# ARA-290

Canonical source: https://retacompare.com/encyclopedia/ara-290

Selective agonist of the innate repair receptor (EPOR/CD131 heteromer) without binding the canonical EPOR — provides EPO's tissue-protective effects without erythropoiesis.

Reference facts

Also known asCibinetide, Helix B Surface PeptideCategoryHealing & Tissue RepairMechanism of actionSelective agonist of the innate repair receptor (EPOR/CD131 heteromer) without binding the canonical EPOR — provides EPO's tissue-protective effects without erythropoiesis.TargetsEPOR/CD131Indications under research or approvedSarcoidosis-related small fibre neuropathy (Phase 2/3), Diabetic neuropathy (research)Regulatory status (reference entry)InvestigationalHalf-life~2 minutes (i.v.)SequenceQEQLERALNSSSequence notes11-residue peptide derived from helix B of erythropoietin (EPO).Molecular weight (Da)1257Originator / sponsorAraim PharmaceuticalsFirst reported2008
    Primary References

Brines et al., Mol Med 2008 (Helix B fragment)


    Explore research articles about ARA-290


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Brines et al., Mol Med 2008 (Helix B fragment): https://pubmed.ncbi.nlm.nih.gov/18369482/